


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I
in which



X denotes CH or N,
R¹ denotes H, A, Hal, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, C(NH)NOH or OCF₃,
R² denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,
R³, R⁴ denote H, (CH₂)_nCO₂R⁵, (CH₂)_nCOH₂, (CH₂)_nCON(R⁵)₂,
(CH₂)_nCOO(CH₂)_nHet, CHO, (CH₂)_nOR⁵, (CH₂)_nHet, (CH₂)_nN(R⁵)₂,
CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nN(R⁵)Het,
(CH₂)_nCH=N-Het, (CH₂)_nOCOR⁵, (CH₂)_nN(R⁵)CH₂CH₂OR⁵,
(CH₂)_nN(R⁵)CH₂CH₂OCF₃, (CH₂)_nN(R⁵)C(R⁵)HCOOR⁵,
(CH₂)_nN(R⁵)CH₂COH₂, (CH₂)_nN(R⁵)CH₂Het,
(CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂COOR⁵,
(CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂,
CH=CHCOOR⁵, CH=CHCH₂NR⁵H₂, CH=CHCH₂N(R⁵)₂,
CH=CHCH₂OR⁵, CH=CHCH₂Het, (CH₂)_nN(R⁵)Ar,
(CH₂)_nN(COOR⁵)COOR⁵, (CH₂)_nN(CONH₂)COOR⁵,
(CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR⁵)COOR⁵,
(CH₂)_nN(CH₂CONH₂)COOR⁵, (CH₂)_nN(CH₂CONH₂)CONH₂,
(CH₂)_nCHR⁵COR⁵, (CH₂)_nCHR⁵COOR⁵, or (CH₂)_nCHR⁵CH₂OR⁵,
where in each case only one of the radicals R³ or R⁴ can have the meaning H,
R⁵ denotes H or A
A denotes straight-chain or branched alkyl having 1 to 10 C atoms,

alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OCOR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,

n denotes 0, 1, 2, 3, 4 or 5, and

Hal denotes F, Cl, Br or I,
or a salt, solvate, enantiomer or racemate thereof.

2. (Previously Presented) A compound according to claim 1, wherein the compound of formula I has a 5-HT receptor-antagonistic action.

3. (Previously Presented) A compound according to claim 1, wherein the compound of formula I has a 5-HT_{2A} receptor-antagonistic action.

4. (Withdrawn) A method according to claim 21, wherein the disease is psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

5. (Withdrawn) A compound according to claim 1, in which R¹ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.

6. (Withdrawn) A compound according to claim 1, in which R³ denotes (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH₂OR⁵, (CH₂)_n-Het, (CH₂)_nN(R⁵)₂, CH=N-OA,

(CH₂)_nN(R⁵)Het, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂Het,
(CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCH₂NR⁵Het,
CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het or (CH₂)_nN(R⁵)Ar.

7. (Withdrawn) A compound according to claim 1, in which R⁴ denotes H.

8. (Previously Presented) A compound according to claim 1, in which R² denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.

9. (Previously Presented) A compound according to claim 1, in which X has the meaning CH.


10. (Cancelled)

11. (Withdrawn) A compound according to claim 1, wherein the compound of formula I is
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-[4-methylpiperazin-1-yl]amine;
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;
4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;
1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;

2-{{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino}ethanol;
 [1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl[methyl]-2-methoxyethyl]amine;
 2-{{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino}ethanol;
 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;
 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-yl[methyl]-4-methylpiperazine; or
 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl[methyl]-methyl-(1-methylpyrrolidin-3-yl)amine;
 or a salt or solvate thereof.

12. (Withdrawn) A method according to claim 21, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

13. (Currently Amended) A compound of formula I
 in which



X denotes CH or N,
 R¹ denotes H, A, Hal, $(CH_2)_n$ Het, $(CH_2)_n$ Ar, ~~cycloalkyl having 3 to 7 C atoms~~, CF_3 , NO_2 , CN, $C(NH)NOH$ or OCF_3 ,
 R² denotes $(CH_2)_n$ Het, $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms or CF_3 ,
 R³, R⁴ denote H, $(CH_2)_nCO_2R^5$, $(CH_2)_nCOH$ et, $(CH_2)_nCON(R^5)_2$,
 $(CH_2)_nCOO(CH_2)_n$ Het, CHO, $(CH_2)_nOR^5$, $(CH_2)_n$ Het, $(CH_2)_nN(R^5)_2$,
 $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nN(R^5)Het$,
 $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^5$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$,
 $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)HCOOR^5$,

$(CH_2)_nN(R^5)CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$,
 $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$,
 $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$,
 $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$,
 $CH=CHCH_2OR^5$, $CH=CHCH_2Het$, $(CH_2)_nN(R^5)Ar$,
 $(CH_2)_nN(COOR^5)COOR^5$, $(CH_2)_nN(CONH_2)COOR^5$,
 $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^5)COOR^5$,
 $(CH_2)_nN(CH_2CONH_2)COOR^5$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^5COR^5$, $(CH_2)_nCHR^5COOR^5$, or $(CH_2)_nCHR^5CH_2OR^5$,
 where in each case only one of the radicals R^3 or R^4 can have the meaning H,
 R^5 denotes H or A
A denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,
Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,
Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR^5 , $OCOR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2 , NH_2 , $NHCOR^5$, CF_3 or SO_2CH_3 ,
n denotes 0, 1, 2, 3, 4 or 5, and
Hal denotes F, Cl, Br or I,
 or a salt thereof.

14. (Withdrawn) A compound according to claim 13, wherein the compound of formula I is

[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1-yl)amine;
 4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;
 4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;

1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;
1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;
2-{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino}ethanol;
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-2-methoxyethyl)amine;
2-{[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino}ethanol;
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1-methylpyrrolidin-3-yl)amine;
or a salt thereof.

15. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 13.

16. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 14.

17. (Withdrawn) A compound according to claim 1, in which R¹ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-

methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,
 R^3 denotes $(CH_2)_nCO_2R^5$, $(CH_2)_nCO-Het$, CHO, CH_2OR^5 , $(CH_2)_n-Het$, $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $(CH_2)_nN(R^5)Het$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)2$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$, $CH=CHCH_2Het$ or $(CH_2)_nN(R^5)Ar$,
 R^4 denotes H,
 R^2 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinoliny, isoquinoliny, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and
 X has the meaning CH.

18. (Withdrawn) A compound according to claim 13, in which
 R^1 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,
 R^3 denotes $(CH_2)_nCO_2R^5$, $(CH_2)_nCO-Het$, CHO, CH_2OR^5 , $(CH_2)_n-Het$, $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $(CH_2)_nN(R^5)Het$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)2$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$, $CH=CHCH_2Het$ or $(CH_2)_nN(R^5)Ar$,
 R^4 denotes H,
 R^2 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinoliny, isoquinoliny, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and
 X has the meaning CH.

19. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 17.

20. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 18.

21. (Withdrawn) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.

22. (Withdrawn) A compound according to claim 13, in which R²denotes Het, Ar, cycloalkyl having 3 to 7 C atoms or CF₃.

23. (Previously Presented) A compound according to claim 13, in which R³, R⁴ denote H, (CH₂)_nCO₂R⁵, (CH₂)_nCOHet, (CH₂)_nCON(R⁵)₂, (CH₂)_nCOO(CH₂)_nHet, CHO, (CH₂)_nOR⁵, (CH₂)_nHet, (CH₂)_nN(R⁵)₂, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nN(R⁵)Het, (CH₂)_nCH=N-Het, (CH₂)_nOCOR⁵, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂OCF₃, (CH₂)_nN(R⁵)C(R⁵)HCOOR⁵, (CH₂)_nN(R⁵)CH₂COHet, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂COOR⁵, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCOOR⁵, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het, (CH₂)_nN(R⁵)Ar, (CH₂)_nN(COOR⁵)COOR⁵, (CH₂)_nN(CONH₂)COOR⁵,

$(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^5)COOR^5$,
 $(CH_2)_nN(CH_2CONH_2)COOR^5$, $(CH_2)_nN(CH_2CONH_2)CONH_2$,
 $(CH_2)_nCHR^5COR^5$, $(CH_2)_nCHR^5COOR^5$, or $(CH_2)_nCHR^5CH_2OR^5$,
where in each case only one of the radicals R^3 or R^4 can have the
meaning H,
wherein, within the definition of R^3 , R^4 , the n is 1, 2, 3, 4 or 5.

24. (Withdrawn) A compound according to claim 23, in which R^2 denotes
Het, Ar, cycloalkyl having 3 to 7 C atoms or CF_3 .